Neuro Vigor Therapeutics is a development stage company focused on reducing reactive aldehyde species, which are significant contributors to multiple diseases, trauma, and pain.

Neuro Vigor Therapeutics

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

H. Lundbeck A/S

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Metric
Company Name	Neuro Vigor Therapeutics	H. Lundbeck A/S	Tonix Pharmaceuticals Holding Corp.
Symbol		LUN	TNXP
MSH ID	COM:NVTHERAPEUTICS	COM:LUNDBECK	COM:TONIXPHARMA
Market	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Drug Manufacturers - Specialty & Generic	Biotechnology
Country	US	DK	US
Stage
Employee Count		5.35K	103
Website	nvtherapeutics.com	lundbeck.com	tonixpharma.com
LinkedIn
Founders

Metric
Market Cap			6.10M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.82B	7.77M
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.18B	3.03M
EBITDA	720.26M	-118.38M
Operating Income	452.47M	-118.38M
Net Income	324.30M	-116.66M
EPS	0.33	-0.01
Diluted EPS	0.33	-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.78	0.13
Operating Profit Margin	0.17	-2.84
EBITDA Margin	0.26	-15.24
Net Profit Margin	0.12	-2.76
Return on Equity	0.11	-0.79
Return on Assets	0.07	-0.73
Return on Capital Employed	0.11	-0.87

COM:NVTHERAPEUTICS

Neuro Vigor Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	26.03	-0.04
P/B Ratio	1.88	0.04
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.89	1.98
EV Multiple	9.97	0.03

Metric
Days Sales Outstanding		15.05
Days Payables Outstanding	391.61	90.73
Days Inventory Outstanding	368.68	276.94
Operating Cycle	448.16	374.77
Cash Conversion Cycle	101.40	144.93
Asset Turnover	0.53	0.27

Metric
Operating Cash Flow	577.80M	-102.00M
Free Cash Flow	506.85M	-109.90M
Cash Flow to Debt	1.23	-8.23
Operating Cash Flow/Sales	0.23	-2.43
Free Cash Flow Yield		-4.38

Metric
Cash & Equivalents	709.50M
Accounts Receivable	-23.65M
Inventory	626.94M	508K
Goodwill	779.88M
Debt to Capitalization	0.23	0.17
Debt to Assets	0.15	0.01
Current Ratio	0.98	1.77
Quick Ratio	1.32	1.56

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.26
R&D to Revenue	0.23	2.49
SG&A to Revenue	0.06	0.59